Your browser doesn't support javascript.
loading
Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group.
Kamat, Ashish M; Apolo, Andrea B; Babjuk, Marek; Bivalacqua, Trinity J; Black, Peter C; Buckley, Roger; Campbell, Matthew T; Compérat, Eva; Efstathiou, Jason A; Grivas, Petros; Gupta, Shilpa; Kurtz, Neil J; Lamm, Donald; Lerner, Seth P; Li, Roger; McConkey, David J; Palou Redorta, Joan; Powles, Thomas; Psutka, Sarah P; Shore, Neal; Steinberg, Gary D; Sylvester, Richard; Witjes, J Alfred; Galsky, Matthew D.
Affiliation
  • Kamat AM; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Apolo AB; Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD.
  • Babjuk M; Department of Urology, Teaching Hospital Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
  • Bivalacqua TJ; Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
  • Black PC; Division of Urology, Department of Surgery, University of Pennsylvania, Philadelphia, PA.
  • Buckley R; Department of Urology, North York General Hospital, Toronto, Ontario, Canada.
  • Campbell MT; Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Compérat E; Department of Pathology, Medical University of Vienna, Vienna, Austria.
  • Efstathiou JA; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
  • Grivas P; Department of Medicine, Division of Oncology, University of Washington; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
  • Gupta S; Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH.
  • Kurtz NJ; Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY.
  • Lamm D; Patient Advocate, Bladder Cancer Advocacy Network (BCAN), Bethesda, MD.
  • Lerner SP; BCG Oncology, Phoenix, AZ.
  • Li R; Scott Department of Urology, Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX.
  • McConkey DJ; Department of Genitourinary Oncology, H Lee Moffitt Cancer Center, Tampa, FL.
  • Palou Redorta J; Johns Hopkins Greenberg Bladder Cancer Institute, Johns Hopkins University, Baltimore, MD.
  • Powles T; Department of Urology, Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Psutka SP; Queen Mary University of London, London, United Kingdom.
  • Shore N; Department of Urology, University of Washington, Fred Hutchinson Cancer Center, Seattle, WA.
  • Steinberg GD; Carolina Urologic Research Center, Myrtle Beach, SC.
  • Sylvester R; Department of Urology, Rush University Medical Center, Chicago, IL.
  • Witjes JA; EAU NMIBC Guidelines Panel, Arnhem, the Netherlands.
  • Galsky MD; Radboud University Medical Center, Nijmegen, the Netherlands.
J Clin Oncol ; 41(35): 5437-5447, 2023 Dec 10.
Article in En | MEDLINE | ID: mdl-37793077
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Carcinoma, Transitional Cell Type of study: Guideline Limits: Humans Language: En Journal: J Clin Oncol Year: 2023 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Carcinoma, Transitional Cell Type of study: Guideline Limits: Humans Language: En Journal: J Clin Oncol Year: 2023 Document type: Article